Advanced search
Publication Cover
Pharmacogenomics Volume 12, 2011 - Issue 4
Submit an article Journal homepage
123
Views
0
CrossRef citations to date
0
Altmetric
Technology Report

APEX Microarray Panel for Genotyping Polymorphisms in Cancer Chemotherapy and Estimation Frequencies in a Slovak Population

Andrea Soltysova1 Department of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská dolina, 842 15Bratislava 4, SlovakiaCorrespondence[email protected]
View further author information
,
Gabriel Minarik1 Department of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská dolina, 842 15Bratislava 4, SlovakiaView further author information
,
Alica Dzurenkova2 Institute of Pathological Physiology, School of Medicine, Comenius University, Sasinkova 4, 811 08Bratislava, SlovakiaView further author information
,
Sabina Sufliarska2 Institute of Pathological Physiology, School of Medicine, Comenius University, Sasinkova 4, 811 08Bratislava, SlovakiaView further author information
,
Ludevit Kadasi1 Department of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská dolina, 842 15Bratislava 4, SlovakiaView further author information
,
Jan Turna1 Department of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská dolina, 842 15Bratislava 4, SlovakiaView further author information
&
Beata Mladosievicova2 Institute of Pathological Physiology, School of Medicine, Comenius University, Sasinkova 4, 811 08Bratislava, SlovakiaView further author information
 show all
Pages 577-592 | Published online: 26 Apr 2011

Bibliography

  • Mladosievicova B , CarterA, KristovaV: Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy.Neoplasma54(3) , 181–188 (2007).
  • Innocenti F , RatainMJ: Update on pharmacogenetics in cancer chemotherapy.Eur. J. Cancer38(5) , 639–644 (2002).
  • Sparreboom A , DanesiR, AndoY, ChanJ, FiggWD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.Drug Resist. Updat.6(2) , 71–84 (2003).
  • Abraham J , EarlHM, PharoahPD, CaldasC: Pharmacogenetics of cancer chemotherapy.Biochim. Biophys. Acta1766(2) , 168–183 (2006).
  • Loktionov A : Common gene polymorphisms, cancer progression and prognosis.Cancer Lett.208(1) , 1–33 (2004).
  • Klein TE , ChangJT, ChoMK et al.: Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base.Pharmacogenomics J.1(3) , 167–170 (2001).
  • Stocco G , MartelossiS, BarabinoA et al.: TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease.Dig. Liver Dis.37(12) , 940–945 (2005).
  • Milek M , MurnJ, JaksicZ, Lukac Bajalo J, Jazbec J, Mlinaric Rascan I: Thiopurine S-methyltransferase pharmacogenetics: genotype to phenotype correlation in the Slovenian population. Pharmacology77(3) , 105–114 (2006).
  • Karas-Kuzelicki N , MilekM, Mlinaric-RascanI: MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females.Clin. Biochem.43(1–2) , 37–42 (2010).
  • Ulrich CM , YasuiY, StorbR et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism.Blood98(1) , 231–234 (2001).
  • Thompson JR , GeraldPF, WilloughbyML, ArmstrongBK: Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case–control study.Lancet358(9297) , 1935–1940 (2001).
  • Molloy AM , ScottJM: Folates and prevention of disease.Public Health Nutr.4(2B) , 601–609 (2001).
  • Cheng Q , WuB, KagerL et al.: A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.Pharmacogenetics14(8) , 557–567 (2004).
  • Organista-Nava J , Gomez-GomezY, Saavedra-HerreraMV et al.: Polymorphisms of the γ-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico.Leuk. Res.34(6) , 728–732 (2010).
  • Etienne MC , LagrangeJL, DassonvilleO et al.: Population study of dihydropyrimidine dehydrogenase in cancer patients.J. Clin. Oncol.12(11) , 2248–2253 (1994).
  • Dai Z , PappAC, WangD, HampelH, WolfgangS: Genotyping panel for assessing response to cancer chemotherapy.BMC Med. Genomics1 , 24 (2008).
  • Rozen S , SkaletskyH: Primer3 on the WWW for general users and for biologist programmers.Methods Mol. Biol.132 , 365–386 (2000).
  • Rosenthal A , CoutelleO, CraxtonM: Large-scale production of DNA sequencing templates by microtitre format PCR.Nucleic Acids Res.21(1) , 173–174 (1993).
  • Pullat J , MetspaluA: Arrayed primer extension reaction for genotyping on oligonucleotide microarray.Methods Mol. Biol.444 , 161–167 (2008).
  • Pemble S , SchroederKR, SpencerSR et al.: Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism.Biochem. J.300(Pt 1) , 271–276 (1994).
  • Bell DA , TaylorJA, PaulsonDF, RobertsonCN, MohlerJL, LucierGW: Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer.J. Natl Cancer Inst.85(14) , 1159–1164 (1993).
  • Cote JF , KirzinS, KramarA et al.: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.Clin. Cancer Res.13(11) , 3269–3275 (2007).
  • Rodriguez S , GauntTR, DayIN: Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies.Am. J. Epidemiol.169(4) , 505–514 (2009).
  • Excoffier L , LavalG, SchneiderS: Arlequin (version 3.0): an integrated software package for population genetics data analysis.Evol. Bioinform. Online1 , 47–50 (2005).
  • Barrett JC : Haploview: visualization and analysis of SNP genotype data.Cold Spring Harb. Protoc.2009(10) , pdb.ip71 (2009).
  • Fung KL , GottesmanMM: A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.Biochim. Biophys. Acta1794(5) , 860–871 (2009).
  • Fukushima-Uesaka H , SaitoY, TohkinM et al.: Genetic variations and haplotype structures of the ABC transporter gene ABCC1 in a Japanese population.Drug Metab. Pharmacokinet.22(1) , 48–60 (2007).
  • Chen J , MaJ, StampferMJ, PalomequeC, SelhubJ, HunterDJ: Linkage disequilibrium between the 677C>T and 1298A>C polymorphisms in human methylenetetrahydrofolate reductase gene and their contributions to risk of colorectal cancer.Pharmacogenetics12(4) , 339–342 (2002).
  • Jones TS , YangW, EvansWE, RellingMV: Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism.Clin. Pharmacol. Ther.81(5) , 729–734 (2007).
  • Dally H , BartschH, JagerB et al.: Genotype relationships in the CYP3A locus in Caucasians.Cancer Lett.207(1) , 95–99 (2004).
  • Banerjee D , Mayer-KuckukP, CapiauxG, Budak-AlpdoganT, GorlickR, BertinoJR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.Biochim. Biophys. Acta1587(2–3) , 164–173 (2002).
  • Genestier L , PaillotR, QuemeneurL, IzeradjeneK, RevillardJP: Mechanisms of action of methotrexate.Immunopharmacology47(2–3) , 247–257 (2000).
  • Stamp LK , ChapmanPT, O‘DonnellJL et al.: Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate.Pharmacogenet. Genomics20(6) , 367–376 (2010).
  • Bohanec GP , LogarD, LestanB, DolzanV: Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism.Eur. J. Clin. Pharmacol.64(11) , 1057–1068 (2008).
  • van der Straaten RJ , WesselsJA, de Vries-Bouwstra JK et al.: Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics8(2) , 141–150 (2007).
  • Dervieux T , KremerJ, LeinDO et al.: Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.Pharmacogenetics14(11) , 733–739 (2004).
  • Chiusolo P , ReddicontoG, FarinaG et al.: MTHFR polymorphisms‘ influence on outcome and toxicity in acute lymphoblastic leukemia patients.Leuk. Res.31(12) , 1669–1674 (2007).
  • Gemmati D , OngaroA, TognazzoS et al.: Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin‘s lymphoma patients: association with toxicity and survival.Haematologica92(4) , 478–485 (2007).
  • Fernandez-Peralta AM , DaimielL, NejdaN, IglesiasD, MedinaAV, Gonzalez-AguileraJJ: Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.Int. J. Colorectal Dis.25(2) , 141–151 (2010).
  • Capitain O , Boisdron-CelleM, PoirierAL, Abadie-LacourtoisieS, MorelA, GamelinE: The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.Pharmacogenomics J.8(4) , 256–267 (2008).
  • van Kuilenburg AB , MullerEW, HaasjesJ et al.: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.Clin. Cancer Res.7(5) , 1149–1153 (2001).
  • Maring JG , van Kuilenburg AB, Haasjes J et al.: Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer86(7) , 1028–1033 (2002).
  • Zhang H , LiYM, ZhangH, JinX: DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.Med. Oncol.24(2) , 251–258 (2007).
  • Gross E , BusseB, RiemenschneiderM et al.: Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.PLoS ONE3(12) , e4003 (2008).
  • Huang MY , FangWY, LeeSC, ChengTL, WangJY, LinSR: ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.BMC Cancer8 , 50 (2008).
  • Caronia D , Patino-GarciaA, MilneRL et al.: Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.Pharmacogenomics J.9(5) , 347–353 (2009).
  • Martinez-Balibrea E , AbadA, ArandaE et al.: Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.Eur. J. Cancer44(9) , 1229–1237 (2008).
  • Stoehlmacher J , GhaderiV, IobalS et al.: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.Anticancer Res.21(4B) , 3075–3079 (2001).
  • Kurzawski M , DziewanowskiK, LenerA, DrozdzikM: TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients.Eur. J. Clin. Pharmacol.65(5) , 533–540 (2009).
  • Tani C , MoscaM, ColucciR et al.: Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases.Clin. Exp. Rheumatol.27(2) , 321–324 (2009).
  • Gazouli M , PachoulaI, PanayotouI et al.: Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.J. Clin. Pharm. Ther.35(1) , 93–97 (2010).
  • Wada M : Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.Cancer Lett.234(1) , 40–50 (2006).
  • Han JY , LimHS, ParkYH, LeeSY, LeeJS: Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.Lung Cancer63(1) , 115–120 (2009).
  • Kim HS , KimMK, ChungHH et al.: Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.Gynecol. Oncol.113(2) , 264–269 (2009).
  • Urayama KY , WienckeJK, BufflerPA, ChokkalingamAP, MetayerC, WiemelsJL: MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia.Cancer Epidemiol. Biomarkers Prev.16(6) , 1172–1177 (2007).
  • Osswald E , JohneA, LaschinskiG et al.: Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers.Eur. J. Clin. Pharmacol.63(1) , 9–16 (2007).
  • Kim WJ , LeeJH, YiJ et al.: A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy.Pharmacogenet. Genomics20(4) , 249–256 (2010).
  • Krupoves A , SeidmanEG, MackD et al.: Associations between ABCB1/MDR1 gene polymorphisms and Crohn‘s disease: a gene-wide study in a pediatric population.Inflamm. Bowel. Dis.15(6) , 900–908 (2009).
  • Warren RB , SmithRL, CampalaniE et al.: Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.J. Invest. Dermatol.128(8) , 1925–1929 (2008).
  • de Jong FA , MarshS, MathijssenRH et al.: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.Clin. Cancer Res.10(17) , 5889–5894 (2004).
  • Wessels JA , KooloosWM, de Jonge R et al.: Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum.54(9) , 2830–2839 (2006).
  • Chandran V , SiannisF, RahmanP, PellettFJ, FarewellVT, GladmanDD: Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis.J. Rheumatol.37(7) , 1508–1512 (2010).
  • Caronia D , Patino-GarciaA, MilneRL et al.: Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.Pharmacogenomics J.9(5) , 347–353 (2009).
  • De JR , HooijbergJH, van Zelst BD et al.: Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood106(2) , 717–720 (2005).
  • Martinez A , MarquezA, MendozaJ et al.: Role of the PXR gene locus in inflammatory bowel diseases.Inflamm. Bowel. Dis.13(12) , 1484–1487 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.